Lentivirus News and Research

RSS
Lentivirus is a genus of slow viruses of the Retroviridae family, characterized by a long incubation period.
Alpaca-derived antibody fragment disrupts interaction between SARS-CoV-2 spike protein and human ACE2

Alpaca-derived antibody fragment disrupts interaction between SARS-CoV-2 spike protein and human ACE2

Exploring SARS-CoV-2 Omicron variant’s neutralizing capacity of booster vaccines

Exploring SARS-CoV-2 Omicron variant’s neutralizing capacity of booster vaccines

Latest tools for COVID-19 Omicron variant research

Latest tools for COVID-19 Omicron variant research

Strategy for capturing SARS-CoV-2 through functionalized cellulose materials

Strategy for capturing SARS-CoV-2 through functionalized cellulose materials

SARS-CoV-2 Omicron variant highly resistant to vaccine-elicited and therapeutic antibodies

SARS-CoV-2 Omicron variant highly resistant to vaccine-elicited and therapeutic antibodies

SARS-CoV-2 Omicron variant neutralized by third BNT162b2 booster shot

SARS-CoV-2 Omicron variant neutralized by third BNT162b2 booster shot

Importance of booster vaccine doses for maintaining protection against the SARS-CoV-2 Omicron variant

Importance of booster vaccine doses for maintaining protection against the SARS-CoV-2 Omicron variant

Iota-carrageenan inhibits replication of SARS-CoV-2 VOCs

Iota-carrageenan inhibits replication of SARS-CoV-2 VOCs

Custom Biofluid & Tissue Procurement Service

Custom Biofluid & Tissue Procurement Service

Immunogenicity of modified microparticle-adjuvanted SARS-CoV-2 vaccine

Immunogenicity of modified microparticle-adjuvanted SARS-CoV-2 vaccine

Broad neutralization capability of potent nanobody against SARS-CoV-2 variants

Broad neutralization capability of potent nanobody against SARS-CoV-2 variants

Novel tetravalent antibodies for the ultrapotent and broad neutralization of SARS-CoV-2 variants

Novel tetravalent antibodies for the ultrapotent and broad neutralization of SARS-CoV-2 variants

Convalescent plasma post-vaccination increases binding and neutralizing antibodies against SARS-CoV-2 variants

Convalescent plasma post-vaccination increases binding and neutralizing antibodies against SARS-CoV-2 variants

Cancer patients have impaired antibody responses to COVID-19 mRNA vaccines

Cancer patients have impaired antibody responses to COVID-19 mRNA vaccines

Increased transmission in open spike conformations of SARS-CoV-2 variants

Increased transmission in open spike conformations of SARS-CoV-2 variants

The role of inhibiting palmitoylation of the SARS-CoV-2 spike protein on viral infectivity

The role of inhibiting palmitoylation of the SARS-CoV-2 spike protein on viral infectivity

Novel Assay Platform for 3D Microfluidic Cancer Research

Novel Assay Platform for 3D Microfluidic Cancer Research

Quantification of antibody titers against SARS-CoV-2 variants elicited by BNT162b2 vaccine

Quantification of antibody titers against SARS-CoV-2 variants elicited by BNT162b2 vaccine

Trial of Sanofi/GSK SARS-CoV-2 vaccine boosters against variants in non-human primates

Trial of Sanofi/GSK SARS-CoV-2 vaccine boosters against variants in non-human primates

Nanoparticles-assisted delivery of antiviral-siRNA for treatment of COVID-19

Nanoparticles-assisted delivery of antiviral-siRNA for treatment of COVID-19